Lamictal Pay-For-Delay Row Shouldn't Be Paused, Buyers Say
Buyers of the anticonvulsant drug Lamictal urged a New Jersey federal judge on Tuesday not to pause discovery in the pay-for-delay case against GlaxoSmithKline and Teva following the U.S. Supreme Court's...To view the full article, register now.
Already a subscriber? Click here to view full article